



**In Vitro Diagnostic Reagent**

# **Clinical Evaluation Report**

**Product Name:** Rapid SARS-CoV-2 Antigen Test Card

**Manufacturer:** MP Biomedicals Germany GmbH

Thueringer Str. 15

37269 Eschwege

Germany

**Report Date:** August 25, 2020



## Table of Contents

ABSTRACT .....	1
1 OVERVIEW .....	2
1.1 INTRODUCTION .....	2
1.1.1 <i>Background for Clinical Trial</i> .....	2
1.1.2 <i>Product Testing Principle and Methods</i> .....	2
1.1.3 <i>Intended Use</i> .....	2
1.2 PURPOSE.....	3
1.3 CLINICAL TRIAL MANAGEMENT .....	3
1.4 EXPERIMENT DESIGN .....	3
1.4.1 <i>Description of Overall Experiment Design and Plan</i> .....	3
1.4.2 <i>Sample Selection and Exclusion Criteria</i> .....	4
1.4.3 <i>Testing Reagent</i> .....	5
1.4.4 <i>Quality Control Methods</i> .....	5
1.4.5 <i>Statistical Analysis Methods</i> .....	5
1.5 CLINICAL TRIAL RESULTS AND ANALYSIS .....	5
1.5.1 <i>Sample distribution statistics</i> .....	5
1.5.2 <i>Statistical analysis of data</i> .....	6
2 APPENDIX .....	6



## Abstract

The clinical diagnosis ability and the in-use safety and effectiveness of the Rapid SARS-CoV-2 Antigen Test Card manufactured by MP Biomedicals Germany GmbH were evaluated based on comparison with the RT-PCR method.

The clinical trials were carried out in strict accordance with the experiment plan. A total of 236 cases were used, including 32 confirmed cases and 204 excluded cases. The test results are summarized below:

Evaluated Reagent Results	RT-PCR Results		Total
	Positive (+)	Negative (-)	
Positive (+)	30	4	34
Negative (-)	2	200	202
Total	32	204	236

Sensitivity =  $30/32 \times 100\% = 93.75\%$  (95% CI: 85.36% - 99.99%)

Specificity =  $200/204 \times 100\% = 98.04\%$  (95% CI: 96.14% - 99.94%)

Accuracy =  $230/236 \times 100\% = 97.46\%$  (95% CI: 95.45% - 99.47%)



## 1 Overview

### 1.1 Introduction

#### 1.1.1 Background for Clinical Trial

COVID-19 is caused by infection with SARS-CoV-2 (novel coronavirus) with major clinical symptoms of fever, cough, and muscle fatigue. The incubation period is 1 to 14 days, mostly 3 to 7 days. A small number of patients can also exhibit nasal congestion, tears, sore throat, myalgia, diarrhea, and other symptoms. Critically ill patients often develop dyspnea and/or hypoxemia one week after disease onset, with severe cases rapidly progressing into acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation disorder, and multiple organ failure. SARS-CoV-2 is an RNA virus belonging to the  $\beta$ -CoV lineage. It has a viral envelope, is round or oval in shape with approximately 60-140 nm in diameter, and is usually polymorphic.

#### 1.1.2 Product Testing Principle and Methods

##### 1. Testing Principle

Rapid SARS-CoV-2 Antigen Test Card is an immunochromatographic lateral flow device that employs the principle of the double antibody sandwich method. Colloidal gold conjugated anti-SARS-CoV-2 antibodies are dry-immobilized on the test device. When the specimen is added, it migrates by capillary diffusion through the strip to re-hydrate the gold conjugate complexes. If present at or above the limit of detection, SARS-CoV-2 viral antigens will react with the gold conjugate complexes to form particles, which will continue to migrate along the strip until the Test Zone (T) where they are captured by the immobilized anti-SARS-CoV-2 antibodies to form a visible red line. If there are no SARS-CoV-2 viral antigens in the specimen, no red line will appear in the Test Zone (T). The gold conjugate complexes will continue to migrate alone until being captured by immobilized antibody in the Control Zone (C) to form a red line, which indicates the validity of the test.

##### 2. Methods

Read the instructions for use carefully before testing. Bring the kit components to room temperature and carry out the test under room temperature.

Refer to the instructions for use for testing procedures.

#### 1.1.3 Intended Use

Rapid SARS-CoV-2 Antigen Test Card is an immunochromatography based one step *in vitro* test. It is designed for the rapid qualitative determination of SARS-CoV-2 virus antigen in nasopharyngeal swabs from individuals suspected of COVID-19 by their healthcare



provider within the first seven days of symptom onset. Rapid SARS-CoV-2 Antigen Test Card cannot be used as the basis to diagnose or exclude SARS-CoV-2 infection.

## **1.2 Purpose**

To evaluate the clinical diagnosis ability and the in-use safety and effectiveness of the Rapid SARS-CoV-2 Antigen Test Card manufactured by MP Biomedicals Germany GmbH.

## **1.3 Clinical Trial Management**


1. Quality control of clinical test conditions and personnel: Before the clinical test is carried out, the department undertaking the clinical test shall check and confirm that the test equipment and instruments are running normally, the reagent is within the effective period and the storage conditions meet the requirements of the kit. Test personnel are trained and able to meet test requirements.
2. Quality control during the clinical trial: This clinical trial adopted a blind controlled trial design, and the samples were blinded. Neither the sample tester nor the result observer knew about the blindness of the samples. It can effectively reduce the bias of test results and ensure the quality of clinical trials. The acquisition, preservation and test operation of samples are carried out in strict accordance with the program, and clinical supervisors are assigned to supervise the implementation of clinical trials.
3. Quality control of clinical trial results: control products are set to ensure the reliable quality of experimental results.
4. The main researcher should appoint experienced personnel in his department to carry out the experiment and judge the results.
5. The operation of clinical trials shall be carried out in strict accordance with standard operating procedures.

## **1.4 Experiment Design**

### **1.4.1 Description of Overall Experiment Design and Plan**

#### **1. Methods**

In this clinical trial, blind data analysis was adopted and the Rapid SARS-CoV-2 Antigen Test Card manufactured by MP Biomedicals Germany GmbH was used to compare and study the detection results of the samples with the RT-PCR method. The specific test process is as follows:



## 2. Selection of Clinical Trial Institutions

The hospital where the clinical trial was conducted has the technical personnel and relevant experience in clinical trial projects to ensure the successful implementation of the clinical trial.

## 3. Number of samples

Confirmed samples: at least 30 cases.

Excluded samples: at least 50 cases.

## 4. Sample type

Nasopharyngeal swab samples from the patients.

### 1.4.2 Sample Selection and Exclusion Criteria

#### 1. Inclusion Criteria:

- a. COVID-19 suspected cases (confirmed cases, excluded cases) were selected.
- b. No limitation on gender and age.
- c. The patient information and clinical test/diagnosis information of the samples can be completely traced.

#### 2. Exclusion Criteria:

- a. Insufficient sample size.
- b. Improper storage of samples.
- c. Others deemed reasonable by the principal investigator.



### 3. Rejection Criteria:

- a. Incomplete case history or failure to meet the inclusion criteria.
- b. The normal test cannot be completed due to equipment or operation factors (the sample is contaminated during operation and the sample size is insufficient).
- c. Samples deemed inappropriate by the principal investigator.

#### 1.4.3 Testing Reagent

##### A. Evaluated Reagent

Reagent Name: Rapid SARS-CoV-2 Antigen Test Card

Manufacturer: MP Biomedicals Germany GmbH

Packaging: 20 tests/kit

Storage: 2-30°C, sealed and stored in dry conditions

##### B. Comparator Method: RT-PCR method

Reagent Name: Detection Kit for 2019-nCoV (PCR-Fluorescence)

#### 1.4.4 Quality Control Methods

1. Adopt unified technical methods in the same laboratory. Evaluation should be performed by the same testing personnel in strict accordance with the reagent operation procedures.
2. Indoor quality control should be carried out for each test.

#### 1.4.5 Statistical Analysis Methods

The sensitivity, specificity, accuracy and confidence interval were calculated by comparing the detection results of the Evaluated Reagent with RT-PCR (see Table 1).

Table 1 Comparison of test results for the Evaluated Reagent and RT-PCR

Evaluated Reagent Results	RT-PCR Results		Total
	Positive (+)	Negative (-)	
Positive (+)	a	b	a+b
Negative (-)	c	d	c+d
Total	a+c	b+d	a+b+c+d

Sensitivity= $a/(a+c) * 100\%$ ;

Specificity= $d/(b+d) * 100\%$ ;

Accuracy= $(a+d)/(a+b+c+d) * 100\%$



## 1.5 Clinical Trial Results and Analysis

### 1.5.1 Sample distribution statistics

A total of 236 samples were used for the clinical trials, including 32 confirmed cases, and 204 excluded cases.

Table 2 Sample Distribution

	Number
Confirmed Cases	32
Excluded Cases	204
Total	236

### 1.5.2 Statistical analysis of data

Table 3 Comparison of test results for the Evaluated Reagent and RT-PCR

Evaluated Reagent Results	RT-PCR Results		Total
	Positive (+)	Negative (-)	
Positive (+)	30	4	34
Negative (-)	2	200	202
Total	32	204	236

Sensitivity =  $30/32 \times 100\% = 93.75\%$  (95% CI: 85.36% - 99.99%)

Specificity =  $200/204 \times 100\% = 98.04\%$  (95% CI: 96.14% - 99.94%)

Accuracy =  $230/236 \times 100\% = 97.46\%$  (95% CI: 95.45% - 99.47%)

## 2 Appendix

Case Report Forms



## Appendix

## Case Report Form

No.	Patient Number	Sex	Age	Sample Type	Clinical Diagnosis Background Info	Evaluated Reagent Results	Nucleic Acid Test Results	Nucleic Acid Testing Value	Disease Onset Time
1	00015164	F	42	Nasopharyngeal Swab	COVID-19	+	+	25	5 days
2	00653145	F	65	Nasopharyngeal Swab	COVID-19	+	+	29	1 day
3	00024862	F	20	Nasopharyngeal Swab	COVID-19	+	+	21.5	3 days
4	00041020	F	38	Nasopharyngeal Swab	COVID-19	+	+	21	1 day
5	00079066	F	72	Nasopharyngeal Swab	COVID-19	+	+	22	3 days
6	00085102	M	66	Nasopharyngeal Swab	COVID-19	+	+	24.3	2 days
7	00070960	F	37	Nasopharyngeal Swab	COVID-19	+	+	23.3	2 days
8	00014950	M	38	Nasopharyngeal Swab	COVID-19	-	+	27	<b>4 days</b>
9	00064687	F	20	Nasopharyngeal Swab	COVID-19	+	+	22.6	2 days
10	00045019	F	26	Nasopharyngeal Swab	COVID-19	+	+	28	7 days
11	00034165	F	53	Nasopharyngeal Swab	COVID-19	+	+	23	1 day
12	00045147	F	86	Nasopharyngeal Swab	COVID-19	+	+	21	3 days
13	00065219	M	56	Nasopharyngeal Swab	COVID-19	+	+	22	4 days
14	00049469	M	58	Nasopharyngeal Swab	COVID-19	+	+	24.2	2 days
15	00085476	M	10	Nasopharyngeal Swab	COVID-19	+	+	23.1	3 days
16	00055367	M	34	Nasopharyngeal Swab	COVID-19	+	+	28	1 day
17	00065069	F	39	Nasopharyngeal Swab	COVID-19	+	+	27.4	2 days
18	00090180	F	47	Nasopharyngeal Swab	COVID-19	+	+	22	2 days
19	00012761	F	61	Nasopharyngeal Swab	COVID-19	+	+	27	6 days
20	00056782	M	30	Nasopharyngeal Swab	COVID-19	+	+	25.5	4 days
21	00043045	F	15	Nasopharyngeal Swab	COVID-19	+	+	23.6	1 day
22	00055198	F	47	Nasopharyngeal Swab	COVID-19	+	+	25.2	2 days
23	00032371	F	29	Nasopharyngeal Swab	COVID-19	+	+	26	2 days



24	00099760	F	49	Nasopharyngeal Swab	COVID-19	+	+	27.1	2 days
25	00056207	F	43	Nasopharyngeal Swab	COVID-19	+	+	31.2	4 days
26	00042236	M	58	Nasopharyngeal Swab	COVID-19	+	+	29	6 days
27	00089182	F	18	Nasopharyngeal Swab	COVID-19	+	+	24	2 days
28	00052691	F	13	Nasopharyngeal Swab	COVID-19	+	+	25	2 days
29	00036306	F	50	Nasopharyngeal Swab	COVID-19	+	+	22.5	2 days
30	00058181	F	55	Nasopharyngeal Swab	COVID-19	+	+	24.4	1 day
31	00024549	M	48	Nasopharyngeal Swab	COVID-19	-	+	26.5	3 days
32	00082479	F	74	Nasopharyngeal Swab	COVID-19	+	+	26.3	4 days
33	00038365	M	70	Nasopharyngeal Swab	AIDS	-	-	>40	/
34	00076707	M	39	Nasopharyngeal Swab	AIDS	-	-	>40	/
35	00040634	M	51	Nasopharyngeal Swab	AIDS	-	-	>40	/
36	00039635	F	38	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
37	QY005248	M	65	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
38	00085216	M	44	Nasopharyngeal Swab	Tuberculous Meningitis	-	-	>40	/
39	00048479	M	22	Nasopharyngeal Swab	Cough to be tested	-	-	>40	/
40	00092844	M	34	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
41	00034321	M	25	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
42	00043099	M	25	Nasopharyngeal Swab	Tuberculosis re-treatment	-	-	>40	/
43	00062236	M	56	Nasopharyngeal Swab	Tuberculosis, Culture-positive, Tracheal Tuberculosis	+	-	>40	/
44	00012535	F	31	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
45	00060272	F	13	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
46	00039324	M	54	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
47	00025899	M	74	Nasopharyngeal Swab	Fever to be tested, Obsolete Tuberculosis,	-	-	>40	/
48	00654962	M	75	Nasopharyngeal Swab	Fever to be tested, Hand Furuncle with Infection?	-	-	>40	/



49	00834102	F	37	Nasopharyngeal Swab	Fever to be tested: 1) bacterial? 2) viral?, Hypothyroidism	+	-	>40	/
50	00454634	F	20	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
51	00619267	F	69	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
52	00126784	F	30	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
53	00449427	M	26	Nasopharyngeal Swab	Fever to be tested: Lung Infection?	-	-	>40	/
54	00383918	F	38	Nasopharyngeal Swab	Pneumonia recovery period	-	-	>40	/
55	00964723	M	9	Nasopharyngeal Swab	URTI?	-	-	>40	/
56	00306115	F	49	Nasopharyngeal Swab	URTI?	-	-	>40	/
57	00130338	M	30	Nasopharyngeal Swab	URTI?	-	-	>40	/
58	00411660	M	37	Nasopharyngeal Swab	URTI?	-	-	>40	/
59	00778439	F	81	Nasopharyngeal Swab	Trochanteric fracture of left femur	-	-	>40	/
60	00583893	M	72	Nasopharyngeal Swab	COPD with acute exacerbation	-	-	>40	/
61	00454385	F	29	Nasopharyngeal Swab	Early Intrauterine Pregnancy	-	-	>40	/
62	00974308	F	53	Nasopharyngeal Swab	Community Acquired Pneumonia	-	-	>40	/
63	00429842	F	21	Nasopharyngeal Swab	Mycoplasma Pneumoniae Pneumonia, Community Acquired Pneumonia	-	-	>40	/
64	00231585	M	38	Nasopharyngeal Swab	Community Acquired Pneumonia, non-severe	-	-	>40	/
65	00414097	M	66	Nasopharyngeal Swab	COPD with acute exacerbation	-	-	>40	/
66	00505685	M	60	Nasopharyngeal Swab	Pulmonary Heart Disease	+	-	>40	/
67	00514175	F	82	Nasopharyngeal Swab	Fell and hurt	-	-	>40	/
68	00534501	F	39	Nasopharyngeal Swab	Early Pregnancy Miscarriage	-	-	>40	/
69	00489143	F	48	Nasopharyngeal Swab	AIDS	-	-	>40	/



70	00765061	M	64	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
71	00527015	M	38	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
72	00567376	M	33	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
73	00850446	M	80	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
74	00844574	M	73	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
75	00724394	M	25	Nasopharyngeal Swab	AIDS	-	-	>40	/
76	00323014	F	54	Nasopharyngeal Swab	AIDS	-	-	>40	/
77	00527445	M	77	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
78	00973853	M	60	Nasopharyngeal Swab	AIDS	-	-	>40	/
79	00489735	M	25	Nasopharyngeal Swab	AIDS	-	-	>40	/
80	00883964	F	14	Nasopharyngeal Swab	Cervical and abdominal lymph node TB	-	-	>40	/
81	00393257	M	78	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
82	00665674	M	84	Nasopharyngeal Swab	Tuberculosis, post-operative multiple-drug resistance	-	-	>40	/
83	00973975	M	57	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
84	00369045	M	65	Nasopharyngeal Swab	Chronic HBV	-	-	>40	/
85	00081637	M	44	Nasopharyngeal Swab	AIDS, Tuberculosis, Drug-induced liver damage	-	-	>40	/
86	00013753	M	37	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
87	00098670	F	28	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
88	00043616	M	21	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
89	00057174	M	40	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
90	00034718	M	75	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
91	00064734	M	35	Nasopharyngeal Swab	Abdominal distention to be tested	-	-	>40	/
92	00081698	F	52	Nasopharyngeal Swab	Liver Cirrhosis	-	-	>40	/
93	00023776	M	49	Nasopharyngeal Swab	HBV	-	-	>40	/
94	00049609	M	51	Nasopharyngeal Swab	Upper Gastrointestinal Bleeding	-	-	>40	/



95	00060356	F	63	Nasopharyngeal Swab	Paravertebral Abscess	-	-	>40	/
96	00056728	M	63	Nasopharyngeal Swab	AIDS, Lung Infection, Headache to be tested	-	-	>40	/
97	00026576	M	23	Nasopharyngeal Swab	Lung Shadow,	-	-	>40	/
98	00032806	M	25	Nasopharyngeal Swab	Cough to be tested	-	-	>40	/
99	00036913	F	30	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
100	00020793	M	66	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
101	00076534	F	31	Nasopharyngeal Swab	Secondary Tuberculosis (re-treatment, multiple drug resistance) smear- and culture-positive, Bronchial Tuberculosis, Drug-Induced Liver Injury, Vitamin B6 deficiency	-	-	>40	/
102	00051375	M	55	Nasopharyngeal Swab	AIDS, fever to be tested	-	-	>40	/
103	00052681	M	35	Nasopharyngeal Swab	AIDS, fever to be tested	-	-	>40	/
104	00013626	F	23	Nasopharyngeal Swab	Fever	-	-	>40	/
105	00046289	M	50	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
106	00059952	M	39	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
107	00019759	M	40	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
108	00038800	M	81	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
109	00055841	M	64	Nasopharyngeal Swab	Fever to be tested?	-	-	>40	/
110	00051978	M	29	Nasopharyngeal Swab	Fever to be tested?	-	-	>40	/
111	00063739	M	10	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
112	00049026	M	36	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
113	00057269	M	23	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
114	00069359	F	34	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/
115	00010804	F	31	Nasopharyngeal Swab	Fever to be diagnosed	-	-	>40	/



116	00057915	M	57	Nasopharyngeal Swab	Fever to be diagnosed, Enteritis?	-	-	>40	/
117	00029877	M	69	Nasopharyngeal Swab	Lung Infection?	-	-	>40	/
118	00081788	M	21	Nasopharyngeal Swab	Acute Tonsillitis	-	-	>40	/
119	00063964	F	39	Nasopharyngeal Swab	URTI?	-	-	>40	/
120	00582121	F	16	Nasopharyngeal Swab	URTI?	-	-	>40	/
121	00036032	F	38	Nasopharyngeal Swab	Intrauterine adhesions following miscarriage, HIV	-	-	>40	/
122	00050514	M	31	Nasopharyngeal Swab	Lung Infection, Fever	-	-	>40	/
123	00059024	M	80	Nasopharyngeal Swab	Asthma to be tested?	-	-	>40	/
124	00009268	M	73	Nasopharyngeal Swab	Community Acquired Pneumonia	-	-	>40	/
125	00039601	F	47	Nasopharyngeal Swab	Chest tightness to be tested	-	-	>40	/
126	00049014	M	61	Nasopharyngeal Swab	HIV, Liver Space Occupying: Primary Liver Cancer	-	-	>40	/
127	00068238	F	54	Nasopharyngeal Swab	Lung Infection, Fever	-	-	>40	/
128	00045269	M	59	Nasopharyngeal Swab	Back pain to be tested	-	-	>40	/
129	00095475	M	88	Nasopharyngeal Swab	COPD with acute exacerbation	-	-	>40	/
130	00657137	F	53	Nasopharyngeal Swab	Bronchial Asthma	-	-	>40	/
131	00036708	M	64	Nasopharyngeal Swab	HBV (HBsAg, HBeAb, and HBeAb positive), Lung Infection	-	-	>40	/
132	00069285	M	82	Nasopharyngeal Swab	Community Acquired Pneumonia, non-severe	-	-	>40	/
133	00035612	M	65	Nasopharyngeal Swab	Foreign body in bronchus? Aspiration Pneumonia	-	-	>40	/
134	00086439	M	83	Nasopharyngeal Swab	Community Acquired Pneumonia, non-severe	-	-	>40	/
135	00044736	M	46	Nasopharyngeal Swab	Chronic HBV, fever	-	-	>40	/
136	00026923	M	51	Nasopharyngeal Swab	Cough to be tested	-	-	>40	/



137	00074580	F	77	Nasopharyngeal Swab	Renal Pelvis Tumor, Acute Gastroenteritis	-	-	>40	/
138	00083392	F	30	Nasopharyngeal Swab	Ectopic Pregnancy	-	-	>40	/
139	00032060	F	62	Nasopharyngeal Swab	HIV, Cervical Cancer	-	-	>40	/
140	00017168	M	72	Nasopharyngeal Swab	Community Acquired Pneumonia	-	-	>40	/
141	00047905	F	82	Nasopharyngeal Swab	COPD with acute exacerbation	-	-	>40	/
142	00035241	F	88	Nasopharyngeal Swab	Fever to be tested? Severe Malnutrition	-	-	>40	/
143	00059469	F	29	Nasopharyngeal Swab	Cough to be tested	-	-	>40	/
144	00047932	F	34	Nasopharyngeal Swab	Community Acquired Pneumonia, non-severe	-	-	>40	/
145	00056163	F	59	Nasopharyngeal Swab	Diabetes	-	-	>40	/
146	00074525	F	36	Nasopharyngeal Swab	HBV (HBsAg, HBeAb, and HBeAb positive), Early Intrauterine Pregnancy	-	-	>40	/
147	00042364	F	55	Nasopharyngeal Swab	Community Acquired Pneumonia, non-severe	-	-	>40	/
148	00035253	M	84	Nasopharyngeal Swab	Lung Infection	-	-	>40	/
149	00038920	M	63	Nasopharyngeal Swab	Pleural Effusion	-	-	>40	/
150	00065262	F	50	Nasopharyngeal Swab	Acute Bronchitis? Community Acquired Pneumonia?	-	-	>40	/
151	00088436	M	77	Nasopharyngeal Swab	Asthma to be tested	-	-	>40	/
152	00042278	M	58	Nasopharyngeal Swab	COPD with acute exacerbation	-	-	>40	/
153	00084568	F	92	Nasopharyngeal Swab	Skin ulcer of both legs to be tested	+	-	>40	/
154	00025729	M	93	Nasopharyngeal Swab	COPD	-	-	>40	/
155	00025884	M	83	Nasopharyngeal Swab	Lung Infection	-	-	>40	/
156	00045779	F	41	Nasopharyngeal Swab	Missed Miscarriage?	-	-	>40	/



157	00035568	M	91	Nasopharyngeal Swab	Fever to be tested, lung infection?	-	-	>40	/
158	00073229	F	51	Nasopharyngeal Swab	Intrauterine Device Incarceration	-	-	>40	/
159	00026516	F	29	Nasopharyngeal Swab	Expected Parturition	-	-	>40	/
160	00083590	F	34	Nasopharyngeal Swab	Expected Parturition	-	-	>40	/
161	00056577	M	50	Nasopharyngeal Swab	HBV (HBsAg, HBeAb, and HBcAb positive), Fever	-	-	>40	/
162	00046085	M	64	Nasopharyngeal Swab	AIDS	-	-	>40	/
163	00658638	M	27	Nasopharyngeal Swab	AIDS	-	-	>40	/
164	00065360	M	33	Nasopharyngeal Swab	AIDS	-	-	>40	/
165	00072834	M	54	Nasopharyngeal Swab	AIDS	-	-	>40	/
166	00047965	M	78	Nasopharyngeal Swab	AIDS	-	-	>40	/
167	00585637	M	30	Nasopharyngeal Swab	AIDS	-	-	>40	/
168	00972618	M	48	Nasopharyngeal Swab	AIDS	-	-	>40	/
169	00049724	F	42	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
170	00045436	M	42	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
171	00085957	M	34	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
172	00016659	F	44	Nasopharyngeal Swab	AIDS	-	-	>40	/
173	00028359	M	26	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
174	00045398	M	52	Nasopharyngeal Swab	AIDS	-	-	>40	/
175	00036615	F	29	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
176	00063164	M	27	Nasopharyngeal Swab	AIDS	-	-	>40	/
177	00084627	M	34	Nasopharyngeal Swab	AIDS	-	-	>40	/
178	QY005618	M	44	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
179	00035639	M	65	Nasopharyngeal Swab	AIDS	-	-	>40	/
180	00654365	M	67	Nasopharyngeal Swab	Tuberculosis, HBV Carrier	-	-	>40	/



181	00056918	M	30	Nasopharyngeal Swab	Secondary Tuberculosis (re-treatment, single drug resistance) smear- and culture-positive, Chronic HBV	-	-	>40	/
182	00048454	M	40	Nasopharyngeal Swab	Tuberculosis, Lung Infection,	-	-	>40	/
183	00069146	M	70	Nasopharyngeal Swab	Tuberculous Pleurisy	-	-	>40	/
184	00062952	F	31	Nasopharyngeal Swab	Tuberculosis, Leukopenia, HBV	-	-	>40	/
185	00075284	M	34	Nasopharyngeal Swab	Secondary Tuberculosis	-	-	>40	/
186	00054267	F	58	Nasopharyngeal Swab	AIDS,	-	-	>40	/
187	00048591	M	28	Nasopharyngeal Swab	HIV	-	-	>40	/
188	00077425	M	64	Nasopharyngeal Swab	Tuberculosis recovered, off drugs and re-checked	-	-	>40	/
189	00076157	M	33	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
190	00072258	M	57	Nasopharyngeal Swab	Tuberculous Meningitis	-	-	>40	/
191	00081291	M	61	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
192	00051446	M	65	Nasopharyngeal Swab	Tuberculosis (drug resistance)	-	-	>40	/
193	00063527	M	43	Nasopharyngeal Swab	AIDS	-	-	>40	/
194	00016662	M	45	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
195	00038469	M	63	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
196	00082663	F	49	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
197	00017591	M	28	Nasopharyngeal Swab	Tuberculous Meningitis	-	-	>40	/
198	00034652	F	22	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
199	00095655	F	55	Nasopharyngeal Swab	NTM	-	-	>40	/
200	00063794	M	53	Nasopharyngeal Swab	AIDS	-	-	>40	/
201	00075368	M	43	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
202	2003101740	F	72	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/
203	2003129839	M	66	Nasopharyngeal Swab	Tuberculosis	-	-	>40	/



204	2003173915	F	13	Nasopharyngeal Swab	Cervical Lymph Node Tuberculosis	-	-	>40	/
205	2003122368	M	40	Nasopharyngeal Swab	Lung Shadow	-	-	>40	/
206	2003195642	M	64	Nasopharyngeal Swab	Tuberculosis, Bronchial Tuberculosis	-	-	>40	/
207	2003174628	F	65	Nasopharyngeal Swab	Chest Pain	-	-	>40	/
208	2003060812	M	29	Nasopharyngeal Swab	AIDS	-	-	>40	/
209	2003061512	F	14	Nasopharyngeal Swab	Bronchial Tuberculosis, Leukopenia	-	-	>40	/
210	2003061841	M	58	Nasopharyngeal Swab	Chronic HBV	-	-	>40	/
211	2003073731	M	51	Nasopharyngeal Swab	Secondary Tuberculosis (re-treatment, multiple drug resistance) smear-negative and culture-positive, Malnutrition, Type II Diabetes	-	-	>40	/
212	2003097466	M	28	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
213	2003099731	M	33	Nasopharyngeal Swab	Sore throat to be tested	-	-	>40	/
214	2003114417	M	37	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
215	2003114831	F	26	Nasopharyngeal Swab	To be tested	-	-	>40	/
216	2003101628	M	42	Nasopharyngeal Swab	Fever, diarrhea, abdominal distention to be tested	-	-	>40	/
217	2003102627	M	22	Nasopharyngeal Swab	Lung lesions to be tested	-	-	>40	/
218	200311573	M	22	Nasopharyngeal Swab	Fever, chest pain	-	-	>40	/
219	2003116517	F	23	Nasopharyngeal Swab	Fever to be tested (JRTI? Salmonellosis?)	-	-	>40	/
220	2003128163	M	37	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
221	2003128736	M	43	Nasopharyngeal Swab	Chest pain to be tested	-	-	>40	/
222	2003129368	F	28	Nasopharyngeal Swab	Pyogenic Tonsillitis	-	-	>40	/
223	2003120471	M	49	Nasopharyngeal Swab	Pharyngeal Bronchitis	-	-	>40	/
224	2003133958	M	18	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/



225	2003145474	M	22	Nasopharyngeal Swab	Fever and emesia to be tested	-	-	>40	/
226	2003161259	M	24	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
227	2003173956	M	48	Nasopharyngeal Swab	Chest tightness to be tested	-	-	>40	/
228	2003174854	M	38	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
229	2003174955	F	48	Nasopharyngeal Swab	Fever: Pharynx Tonsillitis	-	-	>40	/
330	2003191633	M	85	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
231	202007340	M	18	Nasopharyngeal Swab	Cough to be tested	-	-	>40	/
232	202008570	M	36	Nasopharyngeal Swab	Pyogenic Tonsillitis	-	-	>40	/
233	202006479	F	23	Nasopharyngeal Swab	Fever, Sore Throat	-	-	>40	/
234	202008578	M	30	Nasopharyngeal Swab	Fever to be tested	-	-	>40	/
235	202008759	F	47	Nasopharyngeal Swab	Chronic HBV with $\delta$ factor	-	-	>40	/
236	202008236	M	66	Nasopharyngeal Swab	Thoracic Abscess	-	-	>40	/